House Appropriators Sound Off During FDA Hearing About Formula, More Consumer Health Issues
Executive Summary
Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.
You may also be interested in...
Urged By US FDA To Boost Infant Formula Supply, Additional Providers Still Must Wait For Approval
Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.
Biden Mandates Prioritizing Supplies For Infant Formula Production Over All Other Uses
Democrats and Republicans vote to approve $28m emergency finding for FDA formula programs proposed in bill introduced day earlier by Democrat leaders on Appropriations Committee. Biden deems Defense Production Act applicable to manufacturing formula products.
Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use
Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.